Excluding third party contract manufacturing, treating previous year's acquisitions on a like-for-like basis, and excluding the latest purchases, Dechra said its full-year revenues increased by around 7%. In North America Pharmaceuticals revenue growth was around 15%, driven by the companion animal portfolio, which was a strong outperformance of the market, the company noted, even though it was down on the 19.3% seen in the first half of the financial year when a key competitor product was absent from the market. "We are pleased to have delivered another year of strong revenue growth," said Dechra chief executive Ian Page.